Since simvastatin has been shown to inhibit the phosphorylation of rpS6 (Ser235/236; p-rpS6) and mTORC1 signalling in skeletal muscle and contribute to statin-induced myopathy [28], we therefore measured rates of p-rpS6 activation in skeletal muscle lysates of WT and Dysf-null mice treated with simvastatin. Here, DYSF is linked to myopathy.